30.5.2007
News
M&A

KSB represents Glenmark Pharmaceuticals in acquisition of Medicamenta

Law firm Kocián Šolc Balaštík represented Indian pharmaceutical company Glenmark Pharmaceuticals Ltd. in concluding a deal via its Swiss subsidiary Glenmark Holding SA to acquire a majority shareholding in Medicamenta a.s., a company carrying out business activities in the production, sale and marketing of pharmaceutical products in the Czech Republic and Slovakia.

Glenmark Pharmaceuticals Ltd. is the Indian leader in the development of newmolecules in mainly inflammation and metabolic disorders. The company operatesin more than eighty countries worldwide and the acquisition of Medicamenta a.s.represents a strategic entry into two of the fastest growing markets in the EU.

Other articles

5.5.2026
News

EU261 in the Age of the Hormuz Blockade: How Airlines Can Protect Themselves Before the Crisis Peaks

EU261 in the Age of the Hormuz Blockade: How Airlines Can Protect Themselves Before the Crisis Peaks

EU261 in the Age of the Hormuz Blockade: How Airlines Can Protect Themselves Beforethe Crisis Peaks

28.4.2026
News

KŠB advises Olpran in Bikero insolvency proceedings

Kocián Šolc Balaštík has advised bicycle manufacturer Olpran, a notable player in the Czech cycling market, in the insolvency proceedings of Bikero.

Kocián Šolc Balaštík has advised bicycle manufacturer Olpran, a notable player in the Czech cycling market, in the insolvency proceedings of Bikero.

21.4.2026
News

European Commission Proposes Transforming EUSPA into European Union Space Services Agency

On April 7, 2026, the European Commission published a proposal for a regulation establishing the European Union Space Services Agency (EUSSA), amending Regulation (EU) 2021/696. The proposal [COM(2026) 152 final] significantly expands the mandate of the existing EUSPA, headquartered in Prague, and nearly doubles its budget.

On April 7, 2026, the European Commission published a proposal for a regulation establishing the European Union Space Services Agency (EUSSA), amending Regulation (EU) 2021/696. The proposal [COM(2026) 152 final] significantly expands the mandate of the existing EUSPA, headquartered in Prague, and nearly doubles its budget.